Trial results for a Phase 2 study (NCT03069378) investigating pembrolizumab in combination with talimogene laherparepvec (T-VEC) in patients with metastatic and/or locally advanced sarcoma were posted on ClinicalTrials.gov on 2025-10-29. The study, which enrolled 41 participants, reported various counts for Best Objective Response Rate in the combination arm.

Background

The study investigated the combination of talimogene laherparepvec (T-VEC) and pembrolizumab for the treatment of patients with sarcoma, including Epithelioid Sarcoma and Cutaneous Angiosarcoma. The trial aimed to assess the efficacy of this combination therapy in metastatic and/or locally advanced forms of the disease.

Trial design

The study (NCT03069378) was a Phase 2 trial that enrolled 41 participants. It investigated the combination of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with sarcoma, including epithelioid sarcoma and cutaneous angiosarcoma. The trial evaluated the combination therapy in a single arm.

Key results

The trial reported results for the "Best Objective Response Rate" in the arm receiving talimogene laherparepvec (T-VEC) administered with pembrolizumab. The reported counts of participants for this outcome were:

These counts were observed among the 41 enrolled participants.

What this means

The posted results provide initial data on the Best Objective Response Rate for the combination of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with metastatic and/or locally advanced sarcoma. As a Phase 2 study, these findings contribute to the understanding of this combination therapy's activity in this patient population.

Source

The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03069378, titled "A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma," were posted on 2025-10-29 on clinicaltrials.gov.